Breaking Down Nevro: 10 Analysts Share Their Views - Nasdaq

Oct 1, 2024 · Ratings for Nevro (NYSE:NVRO) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.Summarizing their recent …

CouponFollow Extension

$19.62
OFF

What Analysts Are Saying About Nevro Stock | Markets Insider

1 day from now

Jan 12, 2024 · Analysts have set 12-month price targets for Nevro, revealing an average target of $19.62, a high estimate of $23.00, and a low estimate of $15.00.

businessinsider.com

$14.89
OFF

Assessing Nevro: Insights From 9 Financial Analysts

1 day from now

May 8, 2024 · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.89, a high estimate of $19.00, and a low estimate of $11.00.

businessinsider.com

$10.37
OFF

Beyond The Numbers: 6 Analysts Discuss Nevro Stock

1 day from now

Jul 15, 2024 · Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $10.37, with a high estimate of $13.00 and a low estimate of $8.20.

businessinsider.com

$64
OFF

Breaking Down Halozyme Therapeutics: 10 Analysts Share Their …

1 day from now

Nov 20, 2024 · Analysts have set 12-month price targets for Halozyme Therapeutics, revealing an average target of $64.0, a high estimate of $73.00, and a low estimate of $52.00.

benzinga.com

$176
OFF

Breaking Down Masimo: 5 Analysts Share Their Views

1 day from now

6 days ago · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $176.2, a high estimate of $190.00, and a low estimate of $170.00.

benzinga.com

$121
OFF

Breaking Down Natera: 10 Analysts Share Their Views - Nasdaq

1 day from now

Jun 3, 2024 · Analysts have set 12-month price targets for Natera, revealing an average target of $121.8, a high estimate of $142.00, and a low estimate of $100.00.

nasdaq.com

$398.45
OFF

Breaking Down Home Depot: 20 Analysts Share Their Views

1 day from now

Oct 9, 2024 · Analysts have recently evaluated Home Depot and provided 12-month price targets. The average target is $398.45, accompanied by a high estimate of $460.00 and a low estimate …

nasdaq.com

$199
OFF

Breaking Down Ralph Lauren: 10 Analysts Share Their Views

1 day from now

Oct 23, 2024 · Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $199.8, a high estimate of $208.00, and a low estimate …

nasdaq.com

FAQs about Breaking Down Nevro: 10 Analysts Share Their Views - Nasdaq Coupon?

How do analysts evaluate Nevro (Nevro) stock?

Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Nevro compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future value. ...

Is Nevro a good stock to buy?

With a remarkable ROA of -1.5%, the company showcases efficient use of assets and strong financial health. Debt Management: With a high debt-to-equity ratio of 0.74, Nevro faces challenges in effectively managing its debt levels, indicating potential financial strain. Benzinga tracks 150 analyst firms and reports on their stock expectations. ...

How do analysts evaluate Nevro's future value?

Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Nevro's future value. Comparing current and prior targets offers insights into analysts' evolving expectations. ...

Why is Nevro's market capitalization below industry averages?

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity. Positive Revenue Trend: Examining Nevro's financials over 3 months reveals a positive narrative. ...

What challenges does Nevro face with a net margin?

With a net margin of -22.61%, the company may need to address challenges in effective cost control. Return on Equity (ROE): Nevro's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -8.09%, the company may face hurdles in achieving optimal financial performance. ...

How does Benzinga analyze stock expectations?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are. ...